|
|
|
| Clinical effect of Peiyuan Quyu Decoction on treating idiopathic pulmonary fibrosis with phlegm and stasis blocking collaterals |
| DUAN Chenxia DAI Yong ZENG Qigang WEI Chengong LAO Changhui |
| Department of Respiratory Internal Medicine, Guangdong Integrated Chinese and Western Medicine Hospital, Guangdong Province, Foshan 528200, China |
|
|
|
Abstract Objective To explore the clinical effect of Peiyuan Quyu Decoction in treating idiopathic pulmonary fibrosis (IPF) with phlegm and stasis blocking collaterals. Methods From July 2016 to December 2017, 60 patients with IPF in Guangdong Integrated Chinese and Western Medicine Hospital were divided into control group and treatment group by random number table method with 30 cases in each group. The control group was treated with oral Prednisone tablets and the treatment group was treated with Peiyuan Quyu Decoction for 6 months. The clinical effective rate, 6-minute walking distance, quality of life evaluation, shortness degree of breath and changes of lung function were compared between the two groups. Results The total effective rate in the control group was significantly lower than that in the treatment group and the difference is statistically significant (P ＜ 0.05). The 6-minute walking distance, pulmonary function related index, carbon monoxide dispersion (DLCO), ATAQ-IPF score and dyspnea scale (mMRC) grade improved significantly in the treatment group, but the improvement in the control group was not obvious(P ＞ 0.05), the difference between the two groups was statistically significant (P ＜ 0.05). Conclusion Peiyuan Quyu Decoction can improve the clinical symptoms of phlegm and stasis obstruction collaterals type IPF, at the same time, can also improve the pulmonary function parameters, reduce the acute exacerbation of the condition, make life endurance and quality of life significantly improved, and the curative effect is reliable.
|
|
|
|
|
|
[1] 中华医学会呼吸病学分会间质性肺疾病学组·特发性肺纤维化诊断和治疗中国专家共识（2016年修订版）[J].中华结核和呼吸杂志，2016，39（6）：427-432.
[2] Marshall DC，Salciccioli JD，Shea BS，et al. Trends in mortality from idiopathic pulmonary fibrosis in the European Union：an observational study of the WHO mortality database from 2001-2013 [J]. Eur Respir J，2018，51（1）：1701603.
[3] Kishaba T，Nei Y，Momose M，et al. Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis [J]. Eurasian J Med，2018，50（1）：6-10.
[4] Raghu G，Rochwerg B，Zhang Y，et al. An Official ATS/ERS/JRS/ALAT Clinical Practic Guideline：treatment of idiopathic pulmonary fibrosis，An up date of the 2011 clinical practice guideline [J]. AmJ Respir Crit Care Med，2015，192（2）：e3-e19.
[5] Lipsi R，Mazzola D，Caminati A，et al. Severe idiopathic pulmonary fibrosis：A clinical approach [J]. Eur J Intern Med，2018，50：20-27.
[6] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：54-58.
[7] Swigris JJ，Wilson SR，Green KE，et al. Development of the ATAQ-IPF：a tool to assess quality of life in IPF [J]. Health Qual Life Outcomes，2010，8（1）：77.
[8] 王志超，武琦，冯凡超，等.血管紧张素抑制药联合糖皮质激素对特发性肺纤维化作用的系统评价[J].中国临床药理学杂志，2017，33（21）：2182-2186.
[9] 钟春蕾，张志强.糖皮质激素联合N-乙酰半胱氨酸、大环内酯类治疗特发性肺纤维化[J].实用医学杂志，2017， 33（3）：501-502.
[10] 何权瀛.弥漫性肺间质纤维化临床诊断思路[J].临床肺科杂志，2018，23（1）：1-4.
[11] Wallaert B，Masson N，Le OR，et al. Effects of pulmonary rehabilitation on daily life physical activity of fibrotic idiopathic interstitial pneumonia patients [J]. ERJ Open Res，2018，4（2）：00167-2017.
[12] Yount SE，Beaumont JL，Chen SY，et al. Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis [J]. Lung，2016，194（2）：227-234.
[13] 徐飞，崔文强，董竞成.川芎嗪治疗特发性肺纤维化临床疗效的系统评价[J].世界中医药，2016，11（1）：163-168.
[14] 孙明月，王志英.间质性肺疾病的中医临床研究进展[J].湖南中医杂志，2018，34（2）：157-159.
[15] 王海霞，李红，谢海彬，等.特发性肺间质纤维化的研究进展[J].中医临床研究，2017，9（30）：9-12.
[16] 刘妍彤，吕晓东，庞立健，等.通络补络法扭转特发性肺纤维化肺虚络瘀病机的现代医学基础[J].中医杂志，2017，58（16）：1381-1384.
[17] 贾双双，张伟.从脏腑辨证论治间质性肺疾病[J].江苏中医药，2018，50（2）：8-10.
[18] 汪官玉，杨珺超，王真.特发性间质性肺炎的中医治疗研究进展[J].新中医，2018，50（5）：215-218.
[19] 闫雷雷，闫强强，曾学波，等.中医药防治肺纤维化的研究进展及思考[J].湖北中医杂志，2018，40（11）：59-60. |
|
|
|
